Credo Technology Group Azioni (NASDAQ: CRDO)

Credo Technology Group (NASDAQ:CRDO) Azioni

Credo Technology Group

Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.

Dollar General

Markets

CRDO

FERG

MLTX

Tra utili attesi e voci di un deal miliardario, il mercato si muove. Riflettori su retail, tech e una biotech sotto osservazione.

Dollar General, Signet Jewelers e 3 altre azioni da tenere d&#39;occhio oggi

Central,City,Illinois,-,May,2018:,Dollar,General,Sign,Against

Shanghai,,China,-,June,29,,2023:,Saic,Roewe,Feifan,F7

Tech

BPMC

PSTV

SAIC

Tra utili societari, un&#39;acquisizione miliardaria e movimenti after-hours: alcune storie pronte a sfidare il trend di mercato.

Futures in rosso: 5 titoli sotto la lente d&#39;ingrandimento oggi

Credo Technology Group Holding Ltd - Ordinary Shares

Credo Technology Group Holding Ltd

Cerrado Gold Inc

Wells Fargo analyst Elyse Greenspan maintains Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) with a Equal-Weight and raises the price target from $53 to $54.

News

Price Target

Analyst Ratings

Brighthouse Financial, Inc. - Common Stock

Wells Fargo Maintains Equal-Weight on Brighthouse Finl, Raises Price Target to $54

&nbsp;&nbsp;&nbsp;&nbsp;Most people hope to walk into retirement with a nice little nest egg. But what if you&#8217;re staring down a $1.6 million check and wondering, Should I take it — or let the pension ride? That was the exact dilemma one New York City couple brought to Dave Ramsey.
Melissa <a href="https://www.youtube.com/watch?v=-FG5zx8pqeo">called into "The Ramsey Show"</a> to talk about her husband's upcoming retirement and the "final papers" in front of him. At 55 years old, he had a choice: take a $1.6 million lump sum now, or stick with traditional pension payments that would end upon death — or shortly after.
Ramsey didn't hesitate. "There&#8217;s very few times, folks, that you won&#8217;t take the lump sum on a pension," he said. "And that's the reason — 'cause you lose it all when you die. That's it. You get zero."
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
The couple had been offered various survivorship options, including a 100% benefit to Melissa. But Ramsey wasn't impressed. "It only survives one generation past you, though. After that, it&#8217;s gone," he said.
He walked them through the math. If they rolled the lump sum into a traditional IRA and invested <a href="https://www.benzinga.com/personal-finance/25/02/44016490/21-year-old-pro-investor-challenges-dave-ramsey-show-hosts-on-index-funds-vs-mutual-funds-80-of-mutual-funds-dont-beat-the-market">it in a solid mix of mutual funds</a> — not touching the money — Ramsey said, "It'll double about every seven years."
Then came the eye-opener:
"You know, it's going to be $3.2 [million] after 7 years. At 69, it would be about $6 [million], and at 76 it&#8217;ll be… 14."
&nbsp;Melissa's reaction: "Holy mackerel."
&nbsp;Ramsey: "And <a href="https://www.benzinga.com/personal-finance/24/11/41991146/suze-orman-says-this-investment-can-make-your-kids-rich-by-retirement-you-have-a-golden-opportunity-to-launch-them-to-their-first-million">that all goes to your kid</a>. And their kid's kiddos. And so on."
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Compare that to the pension plan, he said, and it's no contest.
"100% of the time, [that money] does not go to them if you leave it in this stinkin' pension."
Ramsey also acknowledged Melissa's concern about market volatility. She mentioned the 2008 crash and the chaos of COVID. Ramsey reminded her of history.
"The Dow went down to 6,500 in 2008. ‘It's at 35,000 this week,' Ramsey said. Before you question the number, that was in 2021. For reference, the Dow's now around 44,829 in 2025, so his point held up."
He told her to zoom out and look at how the market rebounds after events like 9/11, Black Monday, and even Sputnik.
"You've got to get those numbers kind of down in your heart, or you&#8217;re going to freak out with this idea."
He capped it off with this advice:
"You roll it in a direct transfer traditional IRA… invest it in a good mix of mutual funds… and 100% of that money will pass to your heirs. It will not be left behind with a pension plan."
Ramsey didn't just frame it as a financial decision — he made it emotional, generational, and legacy-driven. And in his words, "It's easy math."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence. </a></li>
</ul>
Image: Shutterstock

Personal Finance

55-Year-Old New York City Man Asks If He Should Take $1.6 Million Pension Lump Sum or Monthly Payments – Here's What Dave Ramsey Says To Do

Keefe, Bruyette &amp; Woods analyst Bose George maintains Rocket Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) with a Market Perform and raises the price target from $13 to $14.

Keefe, Bruyette & Woods Maintains Market Perform on Rocket Companies, Raises Price Target to $14

Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) has outperformed the market over the past 5 years by 2.02% on an annualized basis producing an average annual return of 16.39%. Currently, Chubb has a market capitalization of $111.73 billion. 
Buying $100 In CB: If an investor had bought $100 of CB stock 5 years ago, it would be worth $217.64 today based on a price of $278.81 for CB at the time of writing.
<h3>Chubb's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752158805_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Chubb 5 Years Ago Would Be Worth Today

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 100 points on Thursday.
Following the market opening Thursday, the Dow traded up 0.24% to 44,564.14 while the NASDAQ declined 0.44% to 20,520.54. The S&amp;P 500 also fell, dropping, 0.09% to 6,257.81.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46318208/top-2-tech-stocks-that-may-plunge-this-month">Top 2 Tech Stocks That May Plunge This Month</a>
Leading and Lagging Sectors Health care shares jumped by 0.9% on Thursday.
In trading on Thursday, communication services stocks dipped by 1.2%.
Top Headline
U.S. initial jobless claims declined by 5,000 from the previous week to 227,000 in the first week of July, compared to market estimates of 235,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Above Food Ingredients Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVE#NASDAQ">ABVE</a>) shares shot up 330% to $1.53 on continued strength following its merger agreement with Palm Global on Monday.</li>
<li>Shares of DallasNews Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) got a boost, surging 218% to $13.55 after the company announced Hearst will acquire it for $14 per share.</li>
<li>BIT Mining Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NASDAQ">BTCM</a>) shares were also up, gaining 117% to $5.34 after the company announced it plans an investment up to $300 million to expand into the Solana ecosystem.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares dropped 35% to $1.9150. Ultragenyx Pharmaceutical and Mereo BioPharma on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis around the end of the year, consistent with the original plan.</li>
<li>Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) were down 27% to $30.11. Ultragenyx Pharmaceutical and Mereo BioPharma on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis around the end of the year, consistent with the original plan.</li>
<li>CURRENC Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) was down, falling 27% to $1.48 as the company announced the pricing of $60 million underwritten public offering at a price of $5/share.</li>
</ul>
Commodities In commodity news, oil traded down 1.8% to $67.14 while gold traded up 0.1% at $3,322.90.
Silver traded up 0.8% to $36.930 on Thursday, while copper rose 1.8% to $5.5885.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 rose 0.5%, while Spain's IBEX 35 Index fell 0.6%. London's FTSE 100 gained 1.1%, Germany's DAX 40 slipped 0.3% and France's CAC 40 gained 0.3% during the session.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei falling 0.44%, Hong Kong's Hang Seng gaining 0.57%, China's Shanghai Composite gaining 0.48% and India's BSE Sensex falling 0.41%.
Economics
U.S. initial jobless claims declined by 5,000 from the previous week to 227,000 in the first week of July, compared to market estimates of 235,000.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46341009/how-to-earn-500-a-month-from-jpmorgan-stock-ahead-of-q2-earnings">How To Earn $500 A Month From JPMorgan Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

ABVE

BTCM

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

MREO

RARE

US Stocks Mixed; Initial Jobless Claims Fall

Wells Fargo analyst Elyse Greenspan maintains Aflac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>) with a Equal-Weight and raises the price target from $103 to $105.

Wells Fargo Maintains Equal-Weight on Aflac, Raises Price Target to $105

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Ready Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RC#NYSE">RC</a>) with a Underperform and raises the price target from $3.75 to $4.25.

Keefe, Bruyette & Woods Maintains Underperform on Ready Capital, Raises Price Target to $4.25

Wells Fargo analyst Elyse Greenspan maintains Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) with a Overweight and lowers the price target from $387 to $369.

Wells Fargo Maintains Overweight on Willis Towers Watson, Lowers Price Target to $369

WIIM

PTHS

Pelthos Therapeutics shares are trading higher after the company announced the launch of ZELSUVMI topical gel for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older.

Keefe, Bruyette &amp; Woods analyst George Bose maintains PennyMac Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) with a Outperform and raises the price target from $114 to $121.

PFSI

Keefe, Bruyette & Woods Maintains Outperform on PennyMac Financial Servs, Raises Price Target to $121

Wells Fargo analyst Elyse Greenspan maintains Baldwin Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWIN#NASDAQ">BWIN</a>) with a Underweight and raises the price target from $34 to $36.

BWIN

Wells Fargo Maintains Underweight on Baldwin Insurance, Raises Price Target to $36

Wells Fargo analyst Elyse Greenspan maintains Ryan Specialty Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>) with a Equal-Weight and lowers the price target from $65 to $63.

RYAN

Wells Fargo Maintains Equal-Weight on Ryan Specialty Hldgs, Lowers Price Target to $63

Keefe, Bruyette &amp; Woods analyst Bose George maintains AG Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) with a Market Perform and raises the price target from $8.25 to $8.5.

MITT

Keefe, Bruyette & Woods Maintains Market Perform on AG Mortgage IT, Raises Price Target to $8.5

Shares of Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) have soared more than 1000% over the past three months on promising results and breakthrough hopes. Klotho stock was in the spotlight again Thursday after announcing an FDA nod on its ALS <a href="https://www.benzinga.com/markets/penny-stocks/25/06/46171467/this-penny-stock-exploded-500-in-june-what-you-need-to-know">treatment candidate.&nbsp;</a>
<h2 class="wp-block-heading">What's Driving The Rally:&nbsp;</h2>
Klotho announced<a href="https://www.benzinga.com/pressreleases/25/07/n46337387/klotho-neurosciences-inc-granted-fda-orphan-drug-designation-for-klto-202-for-treatment-of-amyotro"> it has received </a>FDA Orphan Drug Designation for its ALS therapy candidate. The official designation unlocks seven years of market exclusivity, tax credits and regulatory assistance as the potential treatment moves through the approval process.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/politics/25/07/46308025/get-ready-for-800-hours-of-blackouts-trumps-doe-warns?utm_source=articleShare">Get Ready For 800 Hours Of Blackouts, Trump&#8217;s DOE Warns</a>&nbsp;
"After the FDA&#8217;s review of the data leading to the Orphan Drug Designation, we believe this ODD designation provides strong validation of our science and our approach to treat this disease,&#8221; said Dr. Joseph Sinkule, Klotho&#8217;s CEO.
Klotho was trading at $1.50 earlier Thursday, which marks a stunning gain of 1,222% from the stock&#8217;s year-to-date low of 11 cents, reached on April 4.&nbsp;
The FDA's orphan drug designation adds to other milestones that have propelled the stock on a wild ride in 2025.&nbsp;
Last month, Klotho <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45841366/klotho-neurosciences-klto-stock-surges-over-680-whats-going-on">announced</a> positive results from a preclinical trial that showed enhancing Klotho gene expression could significantly reduce age-related organ decline and extend lifespan in animal models.&nbsp;
The company <a href="https://www.benzinga.com/markets/penny-stocks/25/06/46171467/this-penny-stock-exploded-500-in-june-what-you-need-to-know">also raised more</a> than $11 million in June through the exercise of existing warrants and eliminated all outstanding debt, resulting in a debt-free balance sheet.
<h2 class="wp-block-heading">Will the Rally Last?</h2>
The stock has seen wild swings and much of the rally is driven by retail enthusiasm, not by revenue or profit growth. Analyst coverage is minimal, and there are no reliable earnings forecasts.
Klotho also faces a potential Nasdaq delisting if it cannot&nbsp; maintain its minimum bid price by August 2025, adding another layer of risk.
<h2 class="wp-block-heading">The Bottom Line</h2>
Klotho stock is on a biotech rollercoaster—soaring on breakthrough hopes, but with volatility and uncertainty sky-high. The rally could continue if clinical progress holds, but investors should brace for sharp twists and turns ahead.&nbsp;
KLTO Stock Price Action: Klotho shares were up 5.8% at $1.44 at the time of publication Thursday, according to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46326465/unitedhealth-slammed-with-another-lawsuit-over-119-billion-stock-plunge?utm_source=articleShare">UnitedHealth Slammed With Another Lawsuit Over $119 Billion Stock Plunge</a></li>
</ul>
Photo: Shutterstock

Biotech

Small Cap

Movers

General

KLTO

Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble?

During Conference Call, Delta Exec Reportedly Says Outlook Reflects Stable Demand Across Both Consumer & Corporate Segments With Midpoint Similar To Q2 Performance

Wells Fargo analyst Elyse Greenspan maintains Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) with a Equal-Weight and raises the price target from $228 to $229.

Wells Fargo Maintains Equal-Weight on Marsh & McLennan Cos, Raises Price Target to $229

Keefe, Bruyette &amp; Woods analyst Bose George downgrades MFA Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFA#NYSE">MFA</a>) from Outperform to Market Perform and lowers the price target from $12 to $10.

Downgrades

Keefe, Bruyette & Woods Downgrades MFA Finl to Market Perform, Lowers Price Target to $10

<a href="https://www.youtube.com/watch?v=K0UwLfevw24">https://www.youtube.com/watch?v=K0UwLfevw24</a>

Macro Notification

Politics

Economics

Fed's Musalem Says So Far It Appears That Reserves Remain Abundant, There Will Be Signals If Reserves Become More Scarce; If The Fed Could Not Pay Interest On Reserves If Could Be Disruptive; Not Paying Intereset On Reserves Would Require More Active Open Market Operations To Control Liquidity; Paying Interest On Reserves Allows The Fed To Inject Liquidity If Needed Without Sacrificing Interest Rate Control

Wells Fargo analyst Elyse Greenspan maintains Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) with a Overweight and raises the price target from $436 to $438.

Wells Fargo Maintains Overweight on Aon, Raises Price Target to $438

Wells Fargo analyst Elyse Greenspan maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Equal-Weight and raises the price target from $70 to $71.

Wells Fargo Maintains Equal-Weight on WR Berkley, Raises Price Target to $71

Press Releases

Credo Files AEC Patent Infringement Complaint Against Amphenol, Molex, TE Connectivity, and Volex with United States International Trade Commission

Credo and XConn to Showcase Seamless GPU Cluster at NVIDIA GTC

WPG Americas Accelerates High-Speed Connectivity Solutions through Credo Partnership

Credo to Showcase AI Scale Out Fabric Featuring Credo Optical DSPs at OFC 2025

Credo Named a Winner of the 2025 Top Workplaces USA Award

Credo Unveils the Lark Family - Setting a New Benchmark for Low-Power 800G Optical DSPs

Credo Schedules Fourth Quarter and Fiscal Year 2025 Financial Results Conference Call

Credo Launches PILOT a Diagnostic and Analytics Software Platform, Enhancing Link Reliability and Performance Across High-Speed Connectivity Solutions

Credo Technology Group Holding Ltd Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Credo to Present at 2025 Mizuho Technology Conference

Analog Devices

Astera Labs

Advanced Micro Devices, Inc. - Common Stock

Advanced Micro Devices

Arm Holdings plc - American Depositary Shares

ARM Holdings

ASE Technology Holding Co., Ltd. American Depositary Shares (each representing Two Common Shares)

Comments

Credo Technology Group

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO